Lund, Sweden, 08.00 CET, 20 February 2019 – BONESUPPORT HOLDING AB (publ) -listed on Nasdaq Stockholm - an emerging leader in Orthobiologics for the management of bone voids, invites to a conference call at 10.00 am on 27 February in connection of the Full Year Report 2018, which is publish... read more

DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that ... read more

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on the Company’s web site at www.oncopeptides.com. The company’s CEO Jakob Lindbe... read more

– Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated– SAN LEANDRO, Calif., February 15, 2019—Rainier Therapeutics, Inc., a privately-held clinical s... read more

Thursday, February 14, 2019 Oslo, Norway, 14 February 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter and full year 2018 results. A meeting for investors, analysts ... read more